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by Schnyder et al. did not include subjects with ho-
mocysteine levels higher than 13.5 µmol per liter.
Studies are needed that will test the efficacy of ho-
mocysteine-lowering vitamin regimens containing
betaine instead of folate.
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EGFR
 
 Mutations and Sensitivity to Gefitinib
 
to the editor: 
 
The important study by Dr. Lynch
and colleagues (May 20 issue)
 
1
 
 suggests that specif-
ic mutations in the epidermal growth factor recep-
tor (EGFR) characterize a subgroup of non–small-
cell lung cancers that may be highly responsive to
gefitinib therapy. Do these mutations predict a
greater sensitivity to chemotherapy as well? The
overall objective response rate to first-line combi-
nation chemotherapy for metastatic non–small-cell
lung cancer is about 20 percent.
 
2
 
 Only tumors from
a small cohort of patients who had a response to ge-
fitinib were studied for the specific mutations, but
all patients except one had also received prior che-
motherapy. Although the authors describe Patient 6
as “representative” of the cohort, the percentage
of other patients who previously had a response to
chemotherapy is not reported. If the rate of response
to first-line chemotherapy was high for the other pa-
tients in the cohort who had a response to gefitinib,
the specific mutations may be predictive of either
chemotherapy or gefitinib sensitivity, thus identify-
ing a distinct subgroup of patients with non–small-
cell lung cancer.
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to the editor: 
 
Lynch et al. and Paez et al.
 
1
 
 report
that mutations in the EGFR kinase domain in lung
cancers are associated with responsiveness to gefi-
tinib. We performed a mutational analysis of the
EGFR kinase region on tumor tissue from nine pa-
tients with an event-free survival of more than 24
weeks in our phase 2 trial of gefitinib in patients
with glioblastoma.
 
2
 
 No mutations affecting the
amino acid sequence in the kinase region were de-
tected. However, our experience with EGFR immu-
nolocalization in brain and lung tumors indicates
that the cytoplasmic and membranous localization
of wild-type EGFR and the constitutively active mu-
tant EGFRvIII in brain tumors as compared with
only membranous localization in lung tumors sup-
ports additional differences in the biology of EGFR
between these tumor systems (McLendon R: per-
sonal communication). In summary, EGFR in glio-
blastoma did not have mutations in the kinase re-
gion, and any activity of gefitinib in glioblastoma
would occur through an alternative mechanism re-
flective of important pathophysiological differenc-
es between glioblastomas and lung carcinomas.
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to the editor: 
 
Lynch et al. elegantly demonstrate
the presence of gain-of-function mutations of EGFR
in patients with non–small-cell lung cancer who had
a response to gefitinib. However, the authors do not
mention whether there were correlations between
mutational findings and the results of immunohis-
tochemical studies or fluorescence in situ hybridi-
zation (FISH), the most commonly used techniques
for detecting EGFR. In fact, we observed that re-
sponsive cases had heterogeneous results of FISH
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analysis, but showed cytoplasm-restricted expres-
sion of EGFR on immunohistochemical evaluation;
conversely, unresponsive cases were negative or dis-
played a cell-membrane staining pattern (unpub-
lished data). In a similar fashion, gastrointestinal
stromal tumor is characterized by activating c-kit
mutations,
 
1
 
 but the gene product, the transmem-
brane tyrosine kinase KIT, is aberrantly expressed
in the cytoplasm, whereas other KIT-positive tu-
mors without c-kit mutations show KIT immuno-
reactivity on cell membranes.
 
2
 
 Successful results
with the use of EGFR and KIT inhibitors are pri-
marily related to gene mutations involving exons
encoding for juxtamembrane protein domains,
 
3
 
possibly leading to cytoplasmic internalization of
mutated tyrosine kinase. If this theory is confirmed,
one can expect therapeutic benefits from the use of
antibodies against EGFR rather than small mole-
cules in lung cancer expressing nonmutated EGFR
at the membrane level.
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the authors reply: 
 
We agree with Dr. Sorscher that
 
EGFR
 
 mutations are likely to identify a discrete ge-
netic subgroup of non–small-cell lung cancers. This
subgroup is uniquely sensitive to gefitinib, but our
study was not designed to test for altered sensitivity
to other chemotherapeutic agents. Gefitinib is cur-
rently approved as third-line therapy in patients with
non–small-cell lung cancer; most of the patients in
our study had previously received chemotherapy and
then subsequently received gefitinib alone. Ongoing
analyses of specimens from larger clinical trials,
which compared chemotherapy with chemotherapy
plus EGFR tyrosine kinase inhibitors, should pro-
vide insight into any differential response to chemo-
therapy by tumors harboring 
 
EGFR
 
 mutations.
In response to Rich et al., the frequent amplifi-
cation of 
 
EGFR
 
 in glioblastomas is well recognized,
as is the presence of in-frame deletions within the
extracellular domain, such as the vIII mutation, re-
sulting in constitutive activation of the receptor.
 
1
 
Gefitinib did not induce dramatic responses in brain
tumors despite these common 
 
EGFR
 
 alterations,
 
2
 
which suggests the  importance of specific muta-
tions within the kinase domain of EGFR. We had not
detected such mutations in four primary glioblasto-
mas and 11 brain-tumor cell lines; the fact that nine
glioblastomas that exhibited modest responses to
gefitinib also lack 
 
EGFR
 
 kinase mutations and do not
show consistent 
 
EGFR
 
 amplification or vIII muta-
tions supports the unique drug susceptibility con-
ferred by the kinase mutations we described. We
cannot comment on unpublished data about cyto-
plasmic as compared with membranous localiza-
tion of EGFR. In addition to altered receptor pro-
cessing, amplification and overexpression of 
 
EGFR
 
itself may well result in stronger signals in both cel-
lular compartments.
In reply to Rossi et al., we note that previous
studies have shown no correlation between respon-
siveness to gefitinib and levels of EGFR expression,
as measured by immunohistochemical analysis.
 
3
 
In the cases we studied, we did not detect amplifi-
cation of either wild-type or mutant 
 
EGFR
 
 alleles.
As noted above, 
 
EGFR
 
 amplification (measured by
FISH) is common in glioblastomas but does not ap-
pear to be correlated with gefitinib responsiveness.
Again, we cannot comment on unpublished data re-
lating to cellular expression patterns of EGFR, but
we note that 
 
EGFR
 
 mutations are within the kinase
domain, not the juxtamembrane domain. We agree
that the effectiveness of antibodies directed against
EGFR needs to be evaluated in mutation-negative
cases.
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